Investors

Press Releases

May 29, 2023

NOTICE OF DEFAULT - UPDATE

May 15, 2023

NOTICE OF DEFAULT - UPDATE

May 9, 2023

AREV IMPLEMENTS AI AS A DRIVING FORCE TO IDENTIFY SCIENCE BACKED COMPOUNDS SYNERGISTIC TO ITS PROPRIETARY EXTRACTS TO INCREASE EFFICACY OF TRADITIONAL MEDICINE

April 27, 2023

AREV Life Sciences Global Corp. Announces Filing of Application for Management Cease Trade Order

March 27, 2023

AREV TERMINATES PRIVATE PLACEMENT AND TERM SHEET WITH FIBERLAB, Inc.

March 15, 2023

AREV Signs Term Sheet with Fiberlab, Inc.

February 28, 2023

AREV Life Sciences Provides Annual Review for 2022 and Operational Update

February 15, 2023

TEAM FROM QUEENSLAND BRAIN INSTITUTE IDENTIFIES NEW HERICERIN DERIVITIVES FROM LIONS MANE THAT BOOST NERVE GROWTH AND ENHANCES MEMORY

January 12, 2023

AREV ISSUES INCENTIVE STOCK OPTIONS

January 6, 2023

Arev Board Change

January 4, 2023

AREV Annual General Meeting Results - January 2023

November 8, 2022

AREV SIGNS TERM SHEET WITH SALT SPRING ISLAND BOTANAMED

October 28, 2022

Dr. Andrew Levinson Joins AREV Life Sciences Global Corporation Scientific Advisory Board

September 22, 2022

AREV NOTES U.S. GOVERNMENTS $2.9 BILLION ASSISTANCE TO ADDRESS FOOD INSECURITY

August 25, 2022

SUSTAINN, AREV’s Ready to Use Therapeutic Foods discussed in leading article in HealthHIV

August 17, 2022

AREV CORPORATE UPDATE

August 17, 2022

AREV ADDS DR. APTE TO THE SAB

August 10, 2022

AREV CORPORATE UPDATE

June 15, 2022

AREV Life Sciences announces acceleration of the clinical development of SUSTAINN, as further predictions of global famine increase demand for Ready to Use Therapeutic Foods (RUTF’s)

May 27, 2022

AREV Life Sciences issues retention warrants